Skip to main content
SpringerLink
Log in

Saturable Active Tubular Reabsorption in the Renal Clearance of Mesalazine in Human Volunteers

  • Clinical Pharmacokinetics
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: To identify the reasons for the large variation in renal clearance of mesalazine.

Design: Data were obtained from a randomised crossover bioequivalence study in 18 healthy volunteers.

Methods: Participants received a single 1000mg oral dose of each of two different formulations of prolonged release mesalazine (2 × 500mg tablets). The formulations had similar dissolution profiles in phosphate buffer pH 6.8. Plasma and urine mesalazine and acetylmesalazine concentrations were determined by validated methods involving high performance liquid chromatography analysis with mass spectrometric detection. Lower limits of quantification were 50 μg/L and 50 μg/L in plasma and 0.25 mg/L and 2 mg/L in urine, respectively.

Results: There was a large variability in the release and absorption of mesalazine from both formulations and in the subsequent renal clearance of mesalazine. There was a clear distinction (p = 0.0009) in renal clearance between volunteers who showed slow mesalazine absorption with subsequent low clearance [0.006 to 0.5 L/h (0.1 to 8 ml/min)] and those who showed more extensive absorption followed by higher renal clearance [0.5 to 6 L/h (8 to 100 ml/min)]. Active tubular reabsorption with a saturable maximum must be the explanation for this difference in renal clearance. The metabolite acetylmesalazine is cleared renally via glomerular filtration and active tubular secretion, resulting in a clearance of 12 to 18 L/h (200 to 300 ml/min).

Conclusion: The renal clearance of mesalazine proceeds via the processes of glomerular filtration and active tubular reabsorption. Tubular reabsorption shows saturation at an area under the plasma concentration-time curve of 4 mg/L·h with an excreted amount of 2mg, resulting in a threshold clearance of 0.5 L/h (8 ml/min). This finding explains the dosage-dependent renal clearance of mesalazine reported in the literature, but has no clear clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Table I

Similar content being viewed by others

References

  1. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98 (5 Pt 1): 1162–9

    PubMed  CAS  Google Scholar 

  2. Prakash A, Markham A. Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn’s disease. Drugs 1999; 57: 383–408

    Article  PubMed  CAS  Google Scholar 

  3. Martindale. Reynolds JEF, editor. The extra pharmacopoeia. 31st ed. Gastro-intestinal agents. Mesalazine. London: Pharmaceutical Press, 1996: 1227–8

  4. Yu DK, Morrill B, Eichmeier LS, et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Eur J Clin Pharmacol 1995; 48: 273–7

    Article  PubMed  CAS  Google Scholar 

  5. Norlander B, Gotthard R, Ström M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn’s disease or ulcerative colitis and in healthy volunteers. Aliment Pharmacol Ther 1990; 4: 497–505

    Article  PubMed  CAS  Google Scholar 

  6. Bondesen S, Hegnhoj J, Larsen F, et al. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. Dig Dis Sci 1991; 36: 1735–40

    Article  PubMed  CAS  Google Scholar 

  7. Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989; 38: 500–23

    Article  PubMed  CAS  Google Scholar 

  8. Järnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 1989; 37: 73–6

    Article  PubMed  Google Scholar 

  9. Meyers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of mesalazine in healthy volunteers given intravenously or released for absorption at different sites in the gastro-intestinal tract. Gut 1987; 28: 196–200

    Article  Google Scholar 

  10. Allgayer H, Sonnenbichler J, Kruis W, et al. Determination of the pK values of 5-aminosalicylic acid and N-acetylsalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites. Arzneimittelforschung 1985; 35: 1457–9

    PubMed  CAS  Google Scholar 

  11. Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal installation in man. Br J Clin Pharmacol 1983; 16: 738–40

    Article  CAS  Google Scholar 

  12. Jacobsen BA, Abildgaard K, Rasmussen HH, et al. Availability of mesalazine from enemas and suppositories during steady state conditions. Scand J Gastroenterol 1991; 26: 374–8

    Article  PubMed  CAS  Google Scholar 

  13. Vree TB, Dammers E, Exler PS, et al. Mono and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in 24 healthy male volunteers controlled by the time of defecation before dosing. J Pharm Pharmacol 2000. In press

  14. Yu DK, Elvin AT, Morrill B, et al. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. Clin Pharmacol Ther 1990; 48: 26–33

    Article  PubMed  CAS  Google Scholar 

  15. Norlander B, Gotthard R, Ström M. Steady-state pharmacokinetics of enteric coated 5-aminosalicylic acid tablets in healthy volunteers and in patients with Crohn’s disease or ulcerative colitis. Aliment Pharmacol Ther 1991; 5: 291–300

    Article  PubMed  CAS  Google Scholar 

  16. Gionchetti P, Campieri M, Belluzzi A, et al. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers. Aliment Pharmacol Ther 1994; 8: 535–40

    Article  PubMed  CAS  Google Scholar 

  17. Vree TB, Hekster YA, Baars AM, et al. Pharmacokinetics of sulphamethoxazole in man: effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole. Clin Pharmacokinet 1978; 3: 319–29

    Article  PubMed  CAS  Google Scholar 

  18. Vree TB, van Ewijk-Beneken Kolmer EWJ, Verwey-Van Wissen CPWM, et al. Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. Int J Clin Pharmacol Ther 1994; 32: 550–8

    PubMed  CAS  Google Scholar 

  19. Boom, SP, Wouterse AC, Vree TB, et al. Renal tubular excretion of the N4-acetyl metabolites of sulphasomidine and sulphadimethoxine in the dog. J Pharm Pharmacol 1993; 45: 614–7

    Article  PubMed  CAS  Google Scholar 

  20. Boom SP, Hoet S, Russel FG. Saturable urinary excretion kinetics of famotidine in the dog. J Pharm Pharmacol 1997; 49: 288–92

    Article  PubMed  CAS  Google Scholar 

  21. Boom SP, Meyer I, Wouterse AC, et al. A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. Biopharm Drug Dispos 1998; 19: 199–208

    Article  PubMed  CAS  Google Scholar 

  22. Bondesen S, Rasmussen SN, Rask-Madsen J, et al. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease. Acta Med Scand 1987; 221: 227–42

    Article  PubMed  CAS  Google Scholar 

  23. Diener U, Tuczek HV, Fischer C, et al. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol 1984; 326: 278–82

    Article  PubMed  CAS  Google Scholar 

  24. Calder IC, Funder CC, Gree CR, et al. Nephrotoxic lesions from 5-aminosalicylic acid. BMJ 1972; 1: 152–4

    Article  PubMed  CAS  Google Scholar 

  25. Noble E, Janssen L, Dierickx PJ. Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines. Cell Biol Toxicol 1997; 13: 445–51

    Article  PubMed  CAS  Google Scholar 

  26. Fraser JS, Smith D, Lamb E, et al. Prospective study of the effect of 5-aminosalicylic acid (mesalazine) on renal function in inflammatory bowel disease [abstract no. 4377]. Proceedings Digestive Disease Week. 1999 May 16–19; Orlando, Florida, USA; 1999: A-794-5

Download references

Author information

Authors and Affiliations

  1. Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

    Tom B. Vree

  2. DADA Consultancy, Nijmegen, The Netherlands

    Erik Dammers

  3. Disphar International, Hengelo (Gld), The Netherlands

    Peter S. Exler

  4. Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany

    Fritz Sörgel

  5. Department of Human Toxicology, University of Utrecht, Utrecht, The Netherlands

    Robert A. A. Maes

Authors
  1. Tom B. Vree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erik Dammers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter S. Exler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fritz Sörgel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert A. A. Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tom B. Vree.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vree, T.B., Dammers, E., Exler, P.S. et al. Saturable Active Tubular Reabsorption in the Renal Clearance of Mesalazine in Human Volunteers. Clin. Drug Investig. 20, 35–42 (2000). https://doi.org/10.2165/00044011-200020010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200020010-00005

Keywords

Search

Navigation